LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-20 | WZ-4-145 | 10.0 | uM | LJP6 | 1 | J19 | 72 | hr | 1657 | 2515 | 5505 | 0.4568 | 0.2228 |
| BT-20 | WZ-4-145 | 10.0 | uM | LJP6 | 2 | J19 | 72 | hr | 1657 | 2492 | 5505 | 0.4526 | 0.2168 |
| BT-20 | WZ-4-145 | 10.0 | uM | LJP6 | 3 | J19 | 72 | hr | 1657 | 2474 | 5505 | 0.4494 | 0.2121 |
| BT-20 | XMD16-144 | 10.0 | uM | LJP5 | 1 | M07 | 72 | hr | 1657 | 1754 | 5505 | 0.3186 | 0.0250 |
| BT-20 | XMD16-144 | 10.0 | uM | LJP5 | 2 | M07 | 72 | hr | 1657 | 2002 | 5505 | 0.3636 | 0.0895 |
| BT-20 | XMD16-144 | 10.0 | uM | LJP5 | 3 | M07 | 72 | hr | 1657 | 1681 | 5505 | 0.3053 | 0.0060 |
| BT-20 | Brivanib | 10.0 | uM | LJP5 | 1 | P13 | 72 | hr | 1657 | 4648 | 5505 | 0.8442 | 0.7771 |
| BT-20 | Brivanib | 10.0 | uM | LJP5 | 2 | P13 | 72 | hr | 1657 | 4507 | 5505 | 0.8186 | 0.7405 |
| BT-20 | Brivanib | 10.0 | uM | LJP5 | 3 | P13 | 72 | hr | 1657 | 4492 | 5505 | 0.8159 | 0.7366 |
| BT-20 | Buparlisib | 10.0 | uM | LJP5 | 1 | H01 | 72 | hr | 1657 | 908 | 5505 | 0.1649 | -0.1948 |
| BT-20 | Buparlisib | 10.0 | uM | LJP5 | 2 | H01 | 72 | hr | 1657 | 994 | 5505 | 0.1805 | -0.1725 |
| BT-20 | Buparlisib | 10.0 | uM | LJP5 | 3 | H01 | 72 | hr | 1657 | 872 | 5505 | 0.1584 | -0.2042 |
| BT-20 | BX-912 | 10.0 | uM | LJP5 | 1 | L19 | 72 | hr | 1657 | 2661 | 5505 | 0.4833 | 0.2607 |
| BT-20 | BX-912 | 10.0 | uM | LJP5 | 2 | L19 | 72 | hr | 1657 | 2619 | 5505 | 0.4757 | 0.2498 |
| BT-20 | BX-912 | 10.0 | uM | LJP5 | 3 | L19 | 72 | hr | 1657 | 2811 | 5505 | 0.5106 | 0.2997 |
| BT-20 | Canertinib | 10.0 | uM | LJP6 | 1 | H07 | 72 | hr | 1657 | 1052 | 5505 | 0.1911 | -0.1574 |
| BT-20 | Canertinib | 10.0 | uM | LJP6 | 2 | H07 | 72 | hr | 1657 | 1303 | 5505 | 0.2367 | -0.0922 |
| BT-20 | Canertinib | 10.0 | uM | LJP6 | 3 | H07 | 72 | hr | 1657 | 1196 | 5505 | 0.2172 | -0.1200 |
| BT-20 | Celastrol | 10.0 | uM | LJP6 | 1 | G07 | 72 | hr | 1657 | 824 | 5505 | 0.1497 | -0.2167 |
| BT-20 | Celastrol | 10.0 | uM | LJP6 | 2 | G07 | 72 | hr | 1657 | 856 | 5505 | 0.1555 | -0.2084 |
| BT-20 | Celastrol | 10.0 | uM | LJP6 | 3 | G07 | 72 | hr | 1657 | 992 | 5505 | 0.1802 | -0.1730 |
| BT-20 | CGP60474 | 10.0 | uM | LJP5 | 1 | F01 | 72 | hr | 1657 | 1351 | 5505 | 0.2454 | -0.0797 |
| BT-20 | CGP60474 | 10.0 | uM | LJP5 | 2 | F01 | 72 | hr | 1657 | 1131 | 5505 | 0.2054 | -0.1369 |
| BT-20 | CGP60474 | 10.0 | uM | LJP5 | 3 | F01 | 72 | hr | 1657 | 1046 | 5505 | 0.1900 | -0.1590 |
| BT-20 | CGP60474 | 10.0 | uM | LJP6 | 1 | G01 | 72 | hr | 1657 | 712 | 5505 | 0.1293 | -0.2458 |